The drugmaker said its submission to the FDA to support authorization of a booster includes data from a phase 3 trial that found a booster dose given 56 days after the first dose was 94 percent effective at preventing symptomatic COVID-19. The trial also showed the booster was 100 percent effective against severe or critical COVID-19 at least 14 days after vaccination.
Data from a phase 1/2a study also showed that a booster of J&J’s COVID-19 vaccine given six months after the first dose increased antibody levels nine-fold one week after the shot and by 12-fold after four weeks.
On the same day, AstraZeneca filed for emergency use authorization from the FDA for its COVID-19 antibody drug for prophylaxis of symptomatic COVID-19.
The drugmaker said clinical trials found the drug caused a 77 percent reduction in risk of developing symptomatic COVID-19, and that the drug has the potential to protect people not expected to have an adequate immune response to a vaccine.
“Vulnerable populations such as the immunocompromised often aren’t able to mount a protective response following vaccination and continue to be at risk of developing COVID-19. With this first global regulatory filing, we are one step closer to providing an additional option to help protect against COVID-19 alongside vaccines,” Menelas Pangalos, PhD, executive vice president of biopharmaceuticals research and development at AstraZeneca, said in a news release.
More than 75 percent of the clinical trial participants had comorbidities associated with an increased risk of severe COVID-19 or a reduced immune response to vaccination.
If authorized, it would be the first antibody drug cleared for COVID-19 prevention.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.